Mepolizumab: Therapeutic strategy for a pediatric patient with eosinophilic granulomatosis with polyangiitis

Pediatr Pulmonol. 2023 Mar;58(3):973-979. doi: 10.1002/ppul.26249. Epub 2022 Dec 5.

Abstract

Eosinophilic granulomatosis with polyangiitis (EGPA; formerly known as Churg-Strauss syndrome) is classified as an antineutrophil cytoplasmic antibody (ANCA)-associated small vessel vasculitis. It is a multisystem disorder and can affect every organ system. EGPA is a rare disease, with an estimated prevalence of 1/70,000-100,000 in Europe. As its onset usually occurs in adulthood, data from pediatric patients are limited. We present here a very rare practical EGPA clinical case involving a pediatric patient. Presently, data on mepolizumab usage in pediatric patients are limited, with only a few case reports published.

Keywords: mepolizumab in pediatrics; pediatric EGPA; small vessel vasculitis.

MeSH terms

  • Antibodies, Antineutrophil Cytoplasmic
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Child
  • Churg-Strauss Syndrome* / complications
  • Churg-Strauss Syndrome* / drug therapy
  • Churg-Strauss Syndrome* / epidemiology
  • Glucocorticoids / therapeutic use
  • Granulomatosis with Polyangiitis* / complications
  • Granulomatosis with Polyangiitis* / drug therapy
  • Humans

Substances

  • mepolizumab
  • Antibodies, Monoclonal, Humanized
  • Glucocorticoids
  • Antibodies, Antineutrophil Cytoplasmic